Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.59 USD | +4.29% | +11.58% | +32.46% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's earnings growth outlook lacks momentum and is a weakness.
- Low profitability weakens the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+32.46% | 312M | C- | ||
+8.29% | 113B | B+ | ||
+10.21% | 106B | B+ | ||
+0.41% | 22.27B | B | ||
-11.90% | 22.22B | B+ | ||
-5.99% | 19.43B | A- | ||
-37.36% | 17.87B | A- | ||
-5.17% | 17.24B | B | ||
+7.70% | 14.29B | C+ | ||
+37.65% | 12.52B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- VNDA Stock
- Ratings Vanda Pharmaceuticals Inc.